ISSN 1662-4009 (online)

ey0020.2-6 | Important for Clinical Practice | ESPEYB20

2.6. Growth patterns of children with short stature in adulthood according to auxological status and maturity at birth

R Pfaffle , M Knupfer , M Gobert , M Vogel , R Gausche , C Beger , E Keller , A Korner , U Thome , W Kiess

Brief summary: This retrospective longitudinal study included 5698 patients with multiple height measurements since birth to the near-adult age. The aim was to define different growth patterns of children from birth to 18 years corrected for gestational age, sex and auxological status at birth in order to early identify children at risk for adult short stature. Adult height was significantly reduced in preterm and/or in small-for-gestational-age (SGA) children, with no sex dif...

ey0020.2-15 | New Perspectives | ESPEYB20

2.15. Childhood height growth rate association with the risk of islet autoimmunity and development of type 1 diabetes

Z Li , R Veijola , E Koski , V Anand , F Martin , K Waugh , H Hyoty , C Winkler , MB Killian , M Lundgren , K Ng , M Maziarz , J Toppari

Brief summary: In this study, 10 145 children of 1–8 years of age, selected from a prospective systematic cohort study and stratified according to HLA-risk categories for type-1-diabetes (T1D), underwent a combined evaluation of pancreatic autoimmunity, glucose metabolism and anthropometry at different timeframes. Diagnosis of T1D occurred in 131/10,145 children (1.3%). Faster height growth, both before and after age 3 years, was significantly associated with the appearan...

ey0020.3-2 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.2. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP

VM Breinholt , PH Mygind , ED Christoffersen , Y Zhang , S Ota , R Will Charlton , D Viuff

In Brief: This phase 1 study in healthy adults assessed the safety and feasibility of transcon-CNP, a novel prodrug that releases native C-type natriuretic peptide (CNP). The novel drug was well tolerated and CNP remained in systemic circulation for >7 days following a single dose.Commentary: Achondroplasia is caused by autosomal activating mutation in the fibroblast growth factor receptor 3 gene (FGFR3) resulting in constitutive receptor ac...

ey0020.4-11 | Psychological Effects of Hormone Treatments | ESPEYB20

4.11. Psychosocial functioning in transgender youth after 2 years of hormones

D Chen , J Berona , YM Chan , D Ehrensaft , R Garofalo , MA Hidalgo , SM Rosenthal , AC Tishelman , J Olson-Kennedy

Brief summary: A four centre prospective longitudinal study of 315 transgender and non-binary adolescents in the USA showed improvement in gender congruence and appearance and some reduction of depression and anxiety (but not in birth-registered males) after 2 years of gender affirming hormone (GAH) treatment.The race is on to provide clear evidence to support hormonal intervention for transgender adolescents. This longitudinal study employed a number of...

ey0020.6-2 | New Mechanisms | ESPEYB20

6.2. Circadian regulation of hippocampal function is disrupted with corticosteroid treatment

MT Birnie , MDB Claydon , O Troy , BP Flynn , M Yoshimura , YM Kershaw , Z Zhao , RCR Demski-Allen , GRI Barker , EC Warburton , ZA Bortolotto , SL Lightman , BL Conway-Campbell

Brief summary: This study investigates the effect of long-acting synthetic glucocorticoids on circadian rhythmicity and hippocampal functionGlucocorticoids exert their effects by binding to glucocorticoid receptors (GRs), which regulate up to ~20% of the genome via both direct (by binding to glucocorticoid responsive elements in promoter regions) and indirect mechanisms (by interacting with bound transcription factors and epigenetic modifiers) (1...

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 7–17 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...

ey0020.9-11 | Obesity as a Brain Disease | ESPEYB20

9.11. Habitual daily intake of a sweet and fatty snack modulates reward processing in humans

SE Thanarajah , AG DiFeliceantonio , K Albus , B Kuzmanovic , L Rigoux , S Iglesias , R Hanszen , M Schlamann , OA Cornely , JC Bruning , M Tittgemeyer , DM Small

Brief summary: This randomized, controlled study in healthy-weight individuals examined the effect of a daily high-fat/high-sugar (HF/HS) intervention over 8 weeks on fat and sugar preference, alterations of brain response to food and sensory associative learning. It addressed the question, whether the association between obesity and altered brain function is pre-existing, is secondary to obesity or is attributed to western diet.Current models of obesity...

ey0020.9-13 | Obesity and Insulin/Glucose Metabolism | ESPEYB20

9.13. Lack of evidence for a causal role of hyperinsulinemia in the progression of obesity in children and adolescents: a longitudinal study

R Halloun , A Galderisi , S Caprio , R Weiss

Brief summary: This longitudinal study aimed to determine if hyperinsulinemia and postprandial glucose levels could predict obesity progression in n=591 children and adolescents with obesity. The authors found no association between hyperinsulinemia, insulin secretion, low postprandial glucose levels, and an increase in obesity over a 2–4-year period.According to the carbohydrate-insulin model (1), diets with a high glycemic load (GL) promote weight...

ey0018.4-13 | New Paradigms | ESPEYB18

4.13 A Genome-wide pharmacogenetic study of growth hormone responsiveness

A Dauber , Y Meng , L Audi , S Vedantam , B Weaver , A Carrascosa , K Albertsson-Wikland , M Ranke , A Jorge , J Cara , MP Wajnrajch , A Lindberg , C Camacho-Hübner , JN Hirschhorn

J Clin Endocrinol Metab. 2020;105:3203–3214. doi: 10.1210/clinem/dgaa443. PMID: 32652002The authors performed a large genome-wide association study (GWAS) to assess the role of common genetic variants in the response to GH therapy. A total of 614 children treated with GH were included: 276 with idiopathic GHD, 297 with ISS, and 41 born SGA. The findings implicate some novel mechanisms...

ey0018.7-1 | Clinical Guidance | ESPEYB18

7.1. Cranial MRI abnormalities and long-term follow-up of the lesions in 770 girls with central precocious puberty

D Helvacıoğlu , S Demircioğlu Turan , T Guran , Z Atay , A Dağcınar , D Bezen , E Karakılıc Ozturan , F Darendeliler , A Yuksel , F Dursun , S Kılınc , S Semiz , S Abalı , M Yıldız , A Onder , A Bereket

J Clin Endocrinol Metab. 2021 Mar 25:dgab190. doi: 10.1210/clinem/dgab190. PMID: 33765130. https://academic.oup.com/jcem/article-abstract/106/7/e2557/6188450?redirectedFrom=fulltextIn brief: This multicentre cohort study explores the frequency, long-term outcomes and potential p...